PRRUF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.03 - $0.33
Previous CloseN/A
Volume11.25K
Average Volume (3M)1.01K
Market Cap
$59.00M
Enterprise Value$10.28
Total Cash (Recent Filing)$68.87M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)―
Beta1.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,473,721,300
10 Day Avg. Volume0
30 Day Avg. Volume1,010
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.27
Price to Sales (P/S)5.36
P/FCF Ratio-1.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sharp Revenue GrowthThe sharp FY2026 revenue increase indicates improving commercial traction and greater monetization of the company’s partnered biotechnology programs. If this growth persists, it can broaden the revenue base, improve operating leverage, and provide a stronger foundation for funding development activities.
Strong Gross Margin ReboundAn approximately 83% gross margin demonstrates attractive underlying economics on the revenue generated in FY2026, despite the company’s clinical-stage status. Sustaining this level would improve the potential for future revenue to contribute meaningfully toward research, development, and corporate costs.
Very Low Financial LeverageMinimal debt materially limits interest expense and debt-servicing pressure, giving Immutep greater flexibility while it develops its pipeline. The positive equity balance also provides some capital buffer, allowing more of its financing capacity to support programs rather than mandatory debt repayment.
Bears Say
Persistent Large Net LossesThe sizeable FY2026 net loss shows that increased revenue has not yet translated into sustainable profitability. Deeply negative operating and net margins indicate that expenses remain high relative to revenue, limiting internal funding capacity and making a durable earnings inflection dependent on further scale or successful programs.
Continued Cash BurnMaterially negative operating and free cash flow means the business continues to consume cash to fund operations and development. Unless operating scale improves, this burn can require repeated external financing, reducing financial flexibility and potentially diverting management attention from advancing the pipeline.
Erosion Of Equity BaseThe sharp reduction in equity reflects the cumulative effect of losses and/or capital structure changes, weakening the company’s financial cushion. With ongoing losses and cash consumption, a smaller equity base increases the importance of future funding and raises the stated risk of dilution for existing shareholders.
Immutep Ltd News
PRRUF FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest stock price was $0.03 and its highest was $0.33 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is $59.00M.
When is Immutep Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immutep Ltd’s earnings last quarter?
Currently, no data Available
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Overvalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in PRRUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PRRUF Sentiment 100%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―
Ownership Overview
2.21% Insiders
0.08% Mutual Funds
― Other Institutional Investors
97.71% Public Companies and
Individual Investors